Johnson David Michael 4

What Happened David M. Johnson, a director of Aura Biosciences (AURA), received equity awards on June 11, 2026: 15,000 restricted stock units (RSUs) and a 30,000-share derivative award. Both items were reported at $0.00 acquisition price (no cash paid). The awards vest in full upon the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to Johnson’s continued service.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (timely within two business days).
• Awards: 15,000 RSUs (acquired, $0.00) and 30,000 derivative award (acquired, $0.00).
• Vesting: Both awards vest in full upon the earlier of (a) June 11, 2027 or (b) the next annual meeting of the issuer’s stockholders, subject to continued service (see footnotes F1 and F5).
• Shares owned after transaction: Not specified in the Form 4.
• Notable footnotes: RSUs described in F1; certain existing shares are held in NEJ09 and NEJ12 irrevocable trusts of which the reporting person is trustee (F2, F3); Reporting Person is sole member of Velosity Capital Management LLC (F4).
• No sale or exercise occurred — these are awards/grants, not cash sales or immediate exercises.

Context These awards are standard equity compensation for insiders and do not involve any immediate sale or cash proceeds. Because the awards vest in the future and require continued service, they do not necessarily indicate near-term trading activity. The filing appears timely.